DeepMed Research

Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Phase 1

Completed

Conditions: Ovarian Cancer
Head and Neck Cancer
Lung Cancer
Melanoma
B-cell Malignancies
Colorectal Cancer (CRC)
Lymphoma
Glioblastoma

Interventions: Drug: Nivolumab
Drug: Epacadostat
Drug: Chemotherapy

First Posted Date: 2014-12-30

Last Posted Date: 2023-04-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 307

Registration Number: NCT02327078

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 20 locations

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Phase 1

Completed

Conditions: UC (Urothelial Cancer)
Head and Neck Cancer
Lung Cancer
Solid Tumors

Interventions: Drug: MEDI4736
Drug: INCB024360

First Posted Date: 2014-12-17

Last Posted Date: 2022-01-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 176

Registration Number: NCT02318277

A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

Phase 1

Terminated

Conditions: UC (Urothelial Cancer)
NSCLC (Non-small Cell Lung Carcinoma)

Interventions: Drug: atezolizumab
Drug: epacadostat

First Posted Date: 2014-11-21

Last Posted Date: 2017-12-11

Lead Sponsor: Incyte Corporation

Target Recruit Count: 29

Registration Number: NCT02298153

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Malignancies
Solid Tumors
Metastatic Cancer

Interventions: Drug: azacitidine
Drug: gemcitabine
Drug: INCB052793
Drug: nab-paclitaxel
Drug: INCB039110
Drug: dexamethasone
Drug: Carfilzomib
Drug: bortezomib
Drug: lenalidomide
Drug: pomalidomide
Drug: INCB050465

First Posted Date: 2014-10-16

Last Posted Date: 2020-04-17

Lead Sponsor: Incyte Corporation

Target Recruit Count: 83

Registration Number: NCT02265510

Locations: 🇺🇸
Site 2, Nashville, Tennessee, United States

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: NSCLC (Non-small Cell Lung Carcinoma)

Interventions: Drug: Itacitinib
Drug: docetaxel

First Posted Date: 2014-10-06

Last Posted Date: 2018-01-25

Lead Sponsor: Incyte Corporation

Target Recruit Count: 9

Registration Number: NCT02257619

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

Completed

Conditions: MPN (Myeloproliferative Neoplasms)

First Posted Date: 2014-09-30

Last Posted Date: 2021-04-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 2544

Registration Number: NCT02252159

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Phase 1

Completed

Conditions: Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
Head and Neck Cancer
Melanoma
Endometrial Cancer
Lung Cancer
Renal Cell Carcinoma (RCC)
Bladder Cancer
Gastric Cancer
Ovarian Cancer
Lymphoma

Interventions: Drug: MK-3475
Drug: INCB024360

First Posted Date: 2014-07-01

Last Posted Date: 2022-02-14

Lead Sponsor: Incyte Corporation

Target Recruit Count: 444

Registration Number: NCT02178722

Locations: 🇺🇸
University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center, Farmington, Connecticut, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Greater Baltimore Cancer Center, Baltimore, Maryland, United States

and more 21 locations

INCB047986 in Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: INCB047986
Drug: Placebo

First Posted Date: 2014-05-30

Last Posted Date: 2015-02-23

Lead Sponsor: Incyte Corporation

Target Recruit Count: 3

Registration Number: NCT02151474

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Ruxolitinib
Drug: Capecitabine
Drug: Placebo

First Posted Date: 2014-04-22

Last Posted Date: 2018-02-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 149

Registration Number: NCT02120417

Study of Ruxolitinib in Colorectal Cancer Patients

Phase 2

Terminated

Conditions: CRC (Colorectal Cancer)

Interventions: Drug: Ruxolitinib
Drug: Regorafenib
Drug: Placebo

First Posted Date: 2014-04-22

Last Posted Date: 2018-02-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 396

Registration Number: NCT02119676

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy